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Genome-wide analysis of canine 
oral malignant melanoma 
metastasis-associated gene 
expression
K. L. Bowlt Blacklock1, Z. Birand1, L. e. selmic2, p. Nelissen3, s. Murphy1,8, L. Blackwood4, 
J. Bass1,9, J. McKay5, R. Fox6, s. Beaver7 & M. starkey1
oral malignant melanoma (oMM) is the most common canine melanocytic neoplasm. overlap between 
the somatic mutation profiles of canine OMM and human mucosal melanomas suggest a shared 
UV-independent molecular aetiology. In common with human mucosal melanomas, most canine 
oMM metastasise. there is no reliable means of predicting canine oMM metastasis, and systemic 
therapies for metastatic disease are largely palliative. Herein, we employed exon microarrays for 
comparative expression profiling of FFPE biopsies of 18 primary canine OMM that metastasised and 
10 primary OMM that did not metastasise. Genes displaying metastasis-associated expression may 
be targets for anti-metastasis treatments, and biomarkers of oMM metastasis. Reduced expression 
of CXCL12 in the metastasising oMMs implies that the CXCR4/CXCL12 axis may be involved in oMM 
metastasis. Increased expression of APOBEC3A in the metastasising oMMs may indicate APOBEC3A-
induced double-strand DNA breaks and pro-metastatic hypermutation. DNA double strand breakage 
triggers the DNA damage response network and two Fanconi anaemia DNA repair pathway members 
showed elevated expression in the metastasising oMMs. Cross-validation was employed to test 
a Linear Discriminant Analysis classifier based upon the RT-qPCR-measured expression levels of 
CXCL12, APOBEC3A and RPL29. Classification accuracies of 94% (metastasising OMMs) and 86% (non-
metastasising oMMs) were estimated.
Oral malignant melanomas (OMMs) are neoplastic proliferations of melanocytes, and are the most common oral 
tumour in dogs1. A predilection for OMM has been consistently suggested for Poodles2,3, and variously suggested 
for Golden Retrievers2, German Shepherd Dogs4 and Boxers4. OMM arise most frequently in the gingiva, but also 
develop in the buccal and labial mucosa, tongue and hard palate5. OMM is characterised by local invasion, recur-
rence after surgical resection, high metastatic propensity, and rapid progression from localised to advanced-stage 
disease4,6. Estimates of OMM metastasis range from 58–74% to regional lymph nodes, 14–67% to the lungs, and 
65% to the tonsils2,3,7. Dogs with regional metastases treated with surgery and or radiotherapy have shorter sur-
vival times than dogs without metastases8. Adjunctive chemotherapy has not been shown to increase survival9, 
and data on the impact of the xenogeneic DNA vaccine10–12 for treatment of advanced OMM is equivocal. A 
median overall survival time of 335 days has been recently reported for OMM patients in receipt of a systemic 
adjuvant therapy following surgical excision of the primary tumour9,13.
Clinicopathological indicators of human cutaneous melanoma malignancy (tumour size and degree of pig-
mentation, presence of necrosis, ulceration or inflammation, rate of cell proliferation, and p53 expression level) 
have limited prognostic utility for canine melanoma, although mitotic index and Ki67 expression level appear to 
be of some value14,15. Canine OMM metastasis cannot be accurately predicted, nor is there an effective approach 
for early detection of metastasis. Cytologic or histologic examination of the mandibular and retropharyngeal 
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lymph nodes is commonly performed during staging, and other lymph nodes may be selected for examination on 
the basis of lymphangiography. However, where OMM metastasis to regional lymph nodes occurs, it is not always 
detected by examination of the mandibular and retropharyngeal lymph nodes16,17.
Whilst OMM represents the most common type of melanoma in dogs3,4,18, oral mucosal melanoma (most 
often developing in the palate and gingiva19) accounts for only 1–8% of all human melanomas and around 0.5% of 
all human oral neoplasms20,21. However, human OMMs are also aggressive rapidly growing, invasive tumours that 
display metastatic rates of 66% (regional lymph nodes22), 53% (lung23), 36% (bone23), and 20% (liver and brain23), 
respectively. The 5-year survival rate is 15–25%22,24. Advanced human mucosal melanoma also has a low rate of 
response to adjuvant chemotherapy25. All human ethnic groups are affected by oral mucosal melanoma, although 
the Japanese appear to have an elevated susceptibility26,27.
Similarities between the somatic mutation profiles of human mucosal melanomas and canine OMMs suggests 
a possible overlapping molecular aetiology for UV-independent tumourigenesis. Putative activating mutations 
in Kit have been described in 7–16% of human mucosal melanomas28,29 and in 12% of canine OMM30, and muta-
tions in NRAS have been reported in 3.9% of canine OMMs3 and in 10–22% of human mucosal melanomas31–33. 
Around 50% of human cutaneous melanomas have an activating BRAF mutation34, but BRAF mutations occur in 
only 4–9.5% of human mucosal melanomas35,36, and have not been found in canine OMMs3.
The metastatic cascade37 comprises a series of steps, which are believed to be at least partially mediated by the 
acquisition of metastasis-associated genetic and/or epigenetic alterations additional to those that drive tumour 
development38. These somatic changes may affect gene expression, and metastasis-associated gene expression 
signatures have been identified for many human tumours39–41. Transcriptional profiling has defined the stages 
in human cutaneous melanoma development and progression as a series of distinct ‘molecular events’, and 
implicated the involvement of sets of genes in the transition from primary to metastatic melanoma42–44. Gene 
expression signatures characteristic of human cutaneous melanoma metastases are detectable in primary cuta-
neous melanomas. A 1,864 gene expression signature derived from profiling cutaneous melanoma metastases 
was subsequently shown to delineate primary melanomas into two classes associated with significantly different 
relapse-free and overall survival45. Integration of functional and structural protein interaction data with primary 
and metastatic melanoma gene expression data enabled derivation of a panel of 6 genes which distinguished 
human primary and metastatic cutaneous melanoma and predicted melanoma-specific survival46. For human oral 
mucosal melanoma, comparative gene expression analysis of lymph node metastases and paired non-metastatic 
lymph nodes has elucidated the involvement of long non-coding RNAs in the regulation of metastasis-associated 
gene expression47. Metastasis-associated gene expression signatures identified in primary tumours may predict 
metastasis, and indeed assay of the expression of 15 genes is the basis of a routine test for human uveal melanoma 
metastasis48.
Gene expression profiling of canine cutaneous melanoma and melanocytoma has implicated the increased 
expression of genes involved in extracellular matrix-receptor interaction and the phosphoinositide 3-kinase/pro-
tein kinase B pathway in metastatic progression49, but no equivalent data is available for the more common canine 
OMM. Although we also recently identified pro-metastatic gene expression in an unrelated canine cancer (mast 
cell tumours50), the overall low degree of ‘overlap’ between the metastatic gene expression signatures identified for 
different human solid tumours41,51 affords the rationale for the gene expression profiling-based study of metastasis 
in different canine cancers, mirroring the approach adopted in the study of human tumour metastasis.
The high rate of mortality attributable to (conventional treatment-resistant) canine OMM metastasis is a sig-
nificant welfare issue. It would be hugely beneficial for clinicians and owners alike to know whether a tumour was 
going to metastasise, while prevention of OMM metastasis would save the lives of most canine OMM patients. 
Establishing the role of dysregulated gene expression in canine OMM metastasis is an opportunity for identifying 
metastasis-associated biomarkers and possible anti-metastasis therapeutic targets.
In this project we performed comparative genome-wide expression profiling of archival biopsies of canine 
primary OMMs that metastasised and did not metastasise. We sought to identify metastasis-associated gene 
expression, and assess whether metastasising and non-metastasising OMMs could be delineated by the expres-
sion levels of genes associated with metastatic progression.
Results
Tumours subject to gene expression profiling. OMM biopsies from 42 dogs [29 bearing a metastasis-
ing (M) tumour and 13 bearing a non-metastasising (NM) tumour] qualified for the study. Through PowerAtlas52 
analysis of human tumour gene expression datasets (from the Gene Expression Omnibus53), it was estimated that 
a ‘Discovery Rate’ of 73.1–81.7% at the 0.05 significance level would be afforded using 20 tumour samples in each 
of two ‘outcome groups’.
Several requests for FFPE OMM biopsies from patients fulfilling the NM inclusion criteria were made to all 
UK veterinary university teaching hospitals and three large multidisciplinary private practices in the UK, but no 
additional NM OMM biopsies could be recruited because of the regular use of xenogeneic vaccination for patients 
regardless of metastatic status at the time of presentation. One NM OMM biopsy was subsequently excluded because 
of a sub-optimal RNA concentration. The integrity of each OMM RNA sample was determined and 20 M OMM and 
12 NM OMM sample groups, with similar RNA integrity ranges, assembled (Tables S1 and S2).
Tumours included in differential expression analysis. Tumours with exon-level probe set expression 
profiles that differed from those of the majority of the 32 OMMs were identified by review of associated sam-
ple quality metrics54, and 2 M and 2 NM OMMs excluded (Tables S2 and S3). The gene-level probe set expres-
sion values in 18 M OMMs and 10 NM OMMs, respectively, were compared for 13,422 Transcript clusters 
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(‘crosshyb_type’ = ‘1’; ‘category’ = ‘main’), for which the expression (above background) of ≥1 exon probe set 
was detected in at least 30% of the OMMs in the M and/or M groups.
The details of the dogs that bore the 18 M OMMs and 10 NM OMMs are presented in Table 1. Tumours in 
the M group were borne by 6 breeds and those in the NM group by 5 breeds. Tumours from Golden Retrievers 
and Labrador Retrievers, and cross bred dogs, were present in both groups. It is likely that the breed representa-
tion of the M and NM OMM groups reflect breed popularity and a predisposition to OMM development2; for 
example, OMMs from 4 Golden Retrievers were present in both the M and NM tumour groups. The median 
ages of the dogs with M and NM OMMs were comparable (10.85 and 10.25 years, respectively), whilst 61% and 
60% of the M and NM OMM dogs were male or neutered male, respectively. No association between OMM gene 
expression profile and either gender, or age at diagnosis, could be gleaned by hierarchical clustering of the 28 
OMMs according to the expression values of the 20% of Transcript Clusters (2,684) that had the highest variance 
in expression signal. Biopsies from 5 of the 8 Golden Retrievers were grouped in a single cluster (together with 
biopsies from a Dachshund and Bullmastiff), whilst the 3 remaining Golden Retriever OMM biopsies were par-
titioned in a second large sub-cluster with biopsies borne by 6 other breeds (Fig. S1). Although this suggests that 
further investigation is warranted to assess the impact of ‘genetic background’ on the somatic molecular profile of 
canine OMMs, from the perspective of identifying metastasis-associated gene expression it is important that the 
8 Golden Retriever OMM biopsies were divided equally between the M and NM OMM groups. Although (after 
‘outlier array’ exclusion) the mean age of a NM OMM FFPE biopsy was 1.6× years higher than the mean age of 
a M OMM FFPE biopsy there was no correlation between FFPE tumour biopsy age and tumour RNA integrity 
(Spearman rank correlation coefficient = 0.09, two-sided p-value: 0.61; Table S2).
Dog ID. Breed Sex Age at diagnosis (Years)
A. Metastasising OMMs
D1 Dachshund FeN 3.5
LR1 Labrador Retriever FeN 12.2
CB1 Cross breed MaN 10.5
CB2 Cross breed FeN 11.0
LR2 Labrador Retriever Ma 11.6
D2 Dachshund FeN 10.8
LR3 Labrador Retriever FeN 11.1
GR1 Golden Retriever FeN 10.9
CS1 Cocker Spaniel Ma 10.0
GR2 Golden Retriever MaN 9.5
CB3 Cross breed FeN 7.8
CB4 Cross breed MaN 10.9
CB5 Cross breed MaN 8.0
GR3 Golden Retriever MaN 10.0
GR4 Golden Retriever Ma 12.4
BM1 Bullmastiff MaN 10.0
CB6 Cross breed Ma 12.0
BC1 Border Collie MaN 12.0
Mean and standard deviation 10.23 ± 2.12
Median 10.85
Interquartile range 1.48
B. Non-metastasising OMMs
GD1 Great Dane FeN 7.0
GR5 Golden Retriever Ma 11.1
GR6 Golden Retriever FeN 12.2
LR4 Labrador Retriever Ma 11.3
LR5 Labrador Retriever Ma 11.4
GR7 Golden Retriever FeN 10.8
IT1 Irish Terrier MaN 4.9
BF1 Bouvier des Flandres MaN 7.6
GR8 Golden Retriever FeN 7.0
CB7 Cross breed MaN 9.7
Mean and standard deviation 9.30 ± 2.48
Median 10.25
Interquartile range 4.10
Table 1. Dogs bearing oral malignant melanomas included in differential gene expression analysis. Fe: Female; 
FeN: Neutered female; Ma: Male; MaN: Neutered male.
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Genes displaying differential expression in M and NM OMMs. In total, 331 Transcript clusters dis-
played a statistically significant difference in expression between M and NM OMMs. Of these, 191 exhibited 
increased expression in the M OMMs (Fig. 1). A >1.5-fold difference in expression between the M and NM 
OMMs was observed for 12 genes (Table 2). Significant sequence similarity to a mRNA encoded by a single 
canine gene was established for a Transcript cluster for which gene annotation was unavailable (Table 2).
Functional annotation enrichment analysis. For Transcript clusters for which an Ensembl Gene ID55 
could be defined, the frequencies of functional annotations assigned to the Transcript clusters differentially 
expressed (300 of 331) between the M and NM OMMs were compared to those assigned to the Transcript clusters 
(11,842 of 13,422) for which the expression (above background) of ≥1 exon probe set was detected in at least 30% 
of the OMMs in the M and/or M groups. Over-represented amongst the genes exhibiting differential expression 
were 4 Gene Ontology Consortium biological processes and one KEGG pathway (Table 3).
RT-qPCR validation of differential expression. The expression, in the 18 M and 10 NM OMMs 
included in differential gene expression analysis, of the 12 genes which displayed >1.5-fold differences in expres-
sion between M and NM OMMs were assayed by RT-qPCR (Table 4). The expression of Small nucleolar RNA 
SNORD61 (which had the lowest median level of expression of the 12 differentially expressed genes) could not 
be measured reliably in the OMM samples (Cq values >35 were obtained, or amplification was not detected), 
although its expression could be detected (Geomean Cq = 27.14) in cDNA prepared from 2 µg of a pool of OMM 
total RNA samples.
For most of the other 11 genes, Cq values ≥35/’undetermined’ and/or a Cq standard deviation (triplicate 
assays) of >35 meant that valid gene expression measurements were recorded for slightly fewer than the 28 OMM 
biopsies profiled by microarray hybridisation. For 8 genes, the expression levels in individual OMMs measured by 
microarray (exon-level probe set) and RT-qPCR, respectively, were highly concordant, as were the NM OMM/M 
OMM fold differences in expression determined by the two techniques (Table 4). For SLC25A51 and SNORA76 
there was a negative correlation between the gene expression values measured by microarray and RT-qPCR, 
and for SLC25A51 there was a difference between the ‘direction’ of NM: M differential expression as assessed by 
microarray and RT-qPCR, respectively (Table 4). These results suggest that for both SLC25A51 and SNORA76 the 
transcript quantified by PCR assay was different to that measured by microarray hybridisation. The differential 
expression of CXCL12 achieved statistical significance.
Class prediction analysis. Based on an evaluation of the relative characteristics of the expression values 
measured for the 13,422 Transcript clusters ‘present’ in the OMMs, the optimal classification function for predic-
tion of OMM ‘metastatic status’ (M or NM) was predicted to be Linear Discriminant Analysis (LDA; predicted 
accuracy = 0.761; lowest predicted accuracy - k-nearest neighbours = 0.408). The ranking of genes for their utility 
in class prediction may be based on the statistical significance of their difference in expression between classes. 
However, ‘filter’ gene selection methods may be based upon other metrics56, including fold-change differences in 
gene expression between classes57,58. Consequently, the efficacy of using the 3 genes shown (by RT-qPCR analy-
sis) to exhibit >two-fold differential expression (Table 4, Fig. 2) for class prediction was tested. The relationships 
between the M and NM OMMs, in the context of the variation in the expression levels of CXCL12, APOBEC3A 
and RPL29, is effectively visualised by principal component analysis (Fig. 3).
Random sampling cross-validation was initially employed to test the performance of the LDA classifier. Two 
M OMMs and 1 NM OMM were randomly selected on each of 20 occasions, and the accuracy of their classifica-
tion (as N or NM) measured after training the classifier using the remaining 15 M and 6 NM OMMs’ expression 
values (Fig. 4). For M OMMs, mean and median classification accuracies of 100% were estimated, whilst mean 
Figure 1. Genes differentially expressed between metastasising and non-metastasising OMMs. Exon 
microarray-measured expression of 331 genes in 18 metastasising (M) and 10 non-metastasising (NM) OMMs. 
The log2-transformed NM/M fold-change (x-axis) denotes the difference in gene expression between the M 
and NM OMMs. The minus log10-transformed permutation testing-adjusted t-test derived p-values (y-axis) 
indicates the statistical significances of gene expression differences. The dotted line illustrates the -log10 PTadj. 
p-value corresponding to a PTadj. p-value = 0.05. Red spheres represent the 3 genes subsequently employed in 
class prediction analysis.
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and median classification accuracies of 65% and 100%, respectively, were estimated for the NM OMMs. In a sub-
sequent evaluation of classifier performance by ‘leave-one-out cross validation’, 94% of 17 M OMMs and 86% of 7 
NM OMMs were correctly classified (Fig. 4).
Discussion
Malignant melanomas are the most common canine melanocytic neoplasm3,4,18 and the most common oral 
malignancy in dogs1. At the present time there is no means to accurately predict if an individual OMM is one of 
the significant proportion of tumours that will metastasise, and metastasis is commonly underestimated during 
tumour staging due to a failure to sample all appropriate lymph nodes, and/or a failure of detection by standard 
cytology or histopathology. Metastasis is the most common cause of death in dogs treated for OMM, but there 
is currently no proven effective therapy to delay or prevent metastasis. With no means of accurately predicting 
OMM metastasis, it is possible that palliative adjuvant treatment is not prescribed for dogs with an unrecognised 
‘metastasising OMM’.
Molecular genetic and epigenetic ‘events’ that promote canine OMM metastasis may be both predictive indi-
cators of canine OMM metastasis and the focus for therapeutics intended to prevent metastasis. Through compar-
ative genome-wide gene expression profiling of 18 primary OMMs that metastasised and 10 primary OMMs that 
did not metastasise, in the present study we aimed to identify dog breed-independent OMM metastasis-associated 
gene expression.
Increased expression in M OMMs characterised 60% of the genes differentially expressed between M 
and NM OMMs. Further indication of the potential significance to OMM metastasis of the ‘up-regulation’ of 
pro-metastatic gene expression is that a similar proportion of the genes differentially expressed between human 
oral mucosal melanoma lymph node metastases and paired non-metastatic lymph nodes were expressed at an 
Gene description (Gene symbol/ID.)
Chromosomal 
locationb
Gene-level fold 
change (NM/M)C Adj_p-valued
PQ loop repeat containing 1 (PQLC1) 1: 0.76 1.72 0.023
Small nucleolar RNA SNORA61 2: 71.92 2.16 0.016
Small nucleolar RNA SNORD104 9: 12.02 1.50 0.030
Dolichyl-phosphate mannosyltransferase polypeptide 2, 
regulatory subunit (DPM2) 9: 55.49 1.51 0.050
Solute carrier family 25, member 51 (SLC25A51) 11: 54.16 1.61 0.016
Ribosomal protein L29 (RPL29) 20: 37.73 1.50 0.019
Small nucleolar RNA SNORA76 27: 36.79 1.70 0.017
Chemokine (C-X-C motif) ligand 12 (CXCL12) 28: 2.90 2.27 0.049
Disintegrin and metalloproteinase domain-containing protein 
10 (ADAM10) 30: 23.61 0.66 0.029
RNA-Binding Motif Protein 3 (RBM3) X: 41.81 1.62 0.013
Small nucleolar RNA SNORD61 X: 107.18 3.33 0.008
Sequence similarity to Apolipoprotein B mRNA editing enzyme 
catalytic subunit 3 A (E-val: 0.0; 375 bp; 88%) (APOBEC3A)a Unknown 0.04 0.025
Table 2. Genes displaying ≥ 1.5-fold differential expression between 18 metastasising and 10 non-metastasising 
OMMs as measured by microarray analysis. aTranscript cluster with no gene annotation. The most significant 
similarity between the sequence (spliced exons) of the Transcript cluster and a canine mRNA is listed. The 
significance of the sequence similarity is denoted by the E value and the length of the sequence alignment, and 
the proportion of the Transcript cluster sequence included in the alignment is stated. bChromosomal location is 
denoted by the chromosome name and the gene start base co-ordinate55. cRatio of median gene-level expression 
values.dPermutation testing-adjusted t-test p-value.
Functional annotationa Fold enrichmentb P-valuec
Gene expression
NM > M M > NM
GO: 0010923 negative regulation of 
phosphatase activity 5.972 0.009 GPATCH2, PPP1R37 CASC5, CHP1, CSRNP2
cfa03460: Fanconi anaemia pathway 4.821 0.018 FANCC FANCB, FANCI, RPA2, TOP3A
GO: 0000266 mitochondrial fission 11.824 0.025 COX10, MUL1 MTFR1
GO: 0010875 positive regulation of 
cholesterol efflux 10.749 0.030 NR1H3, PLTP APOE
GO: 0042632 cholesterol homeostasis 5.086 0.042 NR1H3 ABCA2, APOE, MTTP
Table 3. Differentially expressed gene-associated enriched functional annotations. aGO BP: Gene Ontology 
Biological Process; KP: Kegg Pathway. bFold enrichment - Proportion of 300 differentially expressed genes 
with the functional annotation/proportion of 11,842 genes expressed in the OMM that have the functional 
annotation. cP-value: Fisher Exact test p-value (EASE score) modified to reduce false positive results.
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increased level in the lymph node metastases47. An understanding of the mechanisms by which changes in gene 
expression mediate OMM metastasis is afforded by functional annotation enrichment analysis.
Reversible protein phosphorylation is integral to intracellular signal transduction pathways, and requires the 
coordinated action of protein kinases and protein phosphatases. Disruption of the balance between phosphoryl-
ation and dephosphorylation is associated with carcinogenesis, and protein phosphatases have been recognised 
as tumour suppressors59. Aberrant expression of protein phosphatase inhibitors has been reported in a wide vari-
ety of human cancers60. Two genes (GPATCH2, PPP1R37) with the ‘negative regulation of phosphatase activity’ 
annotation showed decreased expression in the M OMMs and three genes (CASC5, CHP1, CSRNP2) with the 
same annotation showed increased expression in the M OMMs. PPP1R37, GPATCH2 (also known as PPP1R30), 
CASC5 (or PPP1R55) and CSRNP2 (or PPP1R72) encode proteins recognised as inhibitory regulatory subunits 
of phosphoprotein phosphatase 1 (PPP1)61, a protein serine-threonine phosphatase that regulates several mem-
bers of the Transforming growth factor beta signalling pathway62, which promotes invasion and metastasis in 
advanced stages of cancer63. Inhibition of PPP1 by the regulatory subunit PPP1R1A in Ewing sarcoma has been 
shown to promote tumour growth and metastasis64. CHP1 (Calcineurin Homologous Protein 1) inhibits the 
serine/threonine protein phosphatase 2B65, which is responsible for the dephosphorylation (and thus activation) 
Gene symbol/ID.
Exon-level fold changea 
(NM/M)
RT-qPCR
No. NM OMMsb No. M OMMsb
Fold changec 
(NM/M) Spearman RCCd p-valuee
PQLC1 9.26 10 17 1.32 0.52 (0.006) 0.94
SNORA61 2.16 10 17 1.76 0.63 (0.0004) 0.76
SNORD104 1.50 10 16 1.82 0.59 (0.001) 0.76
DPM2 1.90 9 18 1.34 0.49 (0.010) 0.94
SLC25A51 1.61 10 14 0.52 −0.35 (0.097) 0.31
RPL29 1.41 10 17 2.39 0.51 (0.006) 0.34
SNORA76 1.70 6 12 1.12 −0.1 (0.702) 0.94
CXCL12 31.08 10 17 7.14 0.43 (0.024) 0.04
ADAM10 0.42 10 17 0.96 0.41 (0.035) 0.76
RBM3 1.35 10 18 0.95 0.16 (0.425) 0.94
APOBEC3A 0.04 7 17 0.20 0.72 (0.00008) 0.08
Table 4. Differences in gene expression between M and NM OMMs measured by RT-qPCR. aFold change 
difference in expression between 18 M and 10 NM OMMs determined by microarray - Ratio of median 
expression values for the Exon probe set upon which RT-qPCR assay design was based. bThe numbers of NM 
and M OMMs represent the numbers of samples for which valid Cq (Cq < 35; Cq SD < 0.5) measurements 
were. obtained. ‘Non-valid’ Cq values were attributable to: Cq < 35 or ‘undetermined’ and Cq SD > 0.5. cFold 
change (ratio of median expression values) determined by RT-qPCR assay. dThe Spearman rank correlation 
coefficient (RCC) indicates the extent of the concordance between the expression values for individual OMMs 
assayed by microarray and RT-qPCR, respectively.The statistical significance (two-tailed p-value) of the 
correlation is shown in parenthesis. eThe statistical significance of differences between the RT-qPCR measured 
gene expression values for the NM and M OMMs determined by t-test.
Figure 2. RT-qPCR-measured expression levels in OMMs of 3 genes employed in Linear Discriminant Analysis 
classifier. Expression values that encompass those shared by 25% and 75% of the OMMs are denoted by the 
bottom and top of each box, respectively. The median expression value is represented by the line within each 
box, and the maximum and minimum expression values are indicated by the lines extending above and below 
each box, respectively. M = metastasising tumour; NM = Non-metastasising OMM.
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of Nuclear factor of activated T cells (NFAT) transcription factors 1–466. NFATs have been shown to have both 
pro-metastatic67 and anti-metastastic68 activities.
The Fanconi anaemia (FA) pathway is a multi-protein DNA repair pathway that resolves DNA interstrand 
cross-links encountered during DNA replication that would otherwise block replication and transcription, and 
lead to gross chromosome abnormalities69. The pathway forms part of the DNA damage response network70 
which maintains genome integrity. Four genes (FANCB, FANCI, RPA2, TOP3A) with the ‘FA pathway’ annotation 
showed elevated expression in M OMMs, whilst a fifth FA pathway gene (FANCC) displayed marginally decreased 
expression in the M OMMs. FANCB and FANCC encode proteins that form part of the FA core complex, an ubiq-
uitin E3 ligase that monoubiquinates FANCI (and FANCD2), the ID complex, which is subsequently re-localised 
to the DNA lesion, and (with Group III FA proteins) co-ordinates DNA cross-link repair71. The RPA2 and TOP3A 
proteins perform DNA repair functions associated with the FA pathway. RPA2 is a subunit of the Replication 
Protein A complex, which is involved in DNA repair in the cellular response to DNA damage72, whilst TOP3A 
encodes a DNA topoisomerase that controls DNA topology during DNA repair73. The elevated expression of 
Figure 3. Relationship between M and NM OMMs in the context of the expression levels of the genes employed 
for class prediction. Principal component analysis was performed using the RT-qPCR-measured expression 
levels of CXCL12, APOBEC3A and RPL29 in 17 M (red circles) and 7 NM (blue circles) OMMs. The first (PC1) 
and second (PC2) principal components are shown.
Figure 4. Class Prediction by Linear Discriminant Analysis. (A) Random sampling cross-validation. On each 
of 20 occasions, the RT-qPCR-measured expression values of 3 genes (CXCL12, RPL29 and APOBEC3A) which 
displayed >two-fold differential expression between M and NM OMMs were used to predict the class (M = a 
square, and NM = a circle) of 3 randomly-selected OMMs (2 M OMMs and 1 NM OMM, which represent 
10% of the OMMs and constituted a ‘test set’). Prior to class prediction, the LDA classifier was trained using 
the gene expression data obtained for the remaining 90% of the OMMs (15 M and 6 NM OMMs, which 
constituted a ‘training set’). (B) Leave-one-out cross-validation. The RT-qPCR-measured expression values 
of 3 genes (CXCL12, RPL29 and APOBEC3A) which displayed >two-fold differential expression between M 
and NM OMMs were used to predict the class of each of 24 OMMs (17 M = squares, 7 NM = circles). On each 
of 24 occasions, the class of one OMM was predicted after the LDA classifier had been trained using the gene 
expression data obtained for the remaining 23 OMMs. Row 1 depicts the actual class of each OMM and row 2 
the predicted class of each tumour.
8Scientific RepoRts |          (2019) 9:6511  | https://doi.org/10.1038/s41598-019-42839-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
DNA repair pathway genes in human primary cutaneous melanoma has been associated with distant metastasis 
and poor prognosis74. Subsequently, the increased expression of FA and DNA damage response pathway genes 
has been reported in human ‘high grade’ primary cutaneous melanoma (which are associated with significantly 
reduced survival), relative to ‘low grade’ primary tumours45, and in human cutaneous melanoma metastases 
relative to normal skin75. As FA pathway gene expression correlates with FA pathway activity76, it appears that the 
FA pathway is activated in metastasising human cutaneous melanoma and canine OMM. FA pathway activation 
may be a response to increased genome instability in advanced melanomas, and may confer a selective advantage 
supporting metastasis to distant sites.
Two genes (COX10, MUL1)) with the ‘mitochondrial fission’ annotation displayed decreased expression in 
the M OMMs and one gene (MTFR1) with the same annotation showed elevated expression in the M OMMs. 
Increased expression of mitochondrial fission pathway genes has been associated with the invasiveness and 
metastasis of some cancers77,78. MTFR1 (Mitochondrial Fission Regulator 1) is upregulated in metastatic uveal 
melanoma79, and is a member of a 20-gene panel whose collective high expression is predictive of prostate cancer 
metastasis80. Conversely, suppression of MUL1 (Mitochondrial E3 Ubiquitin Protein Ligase 1) has been associ-
ated with the progression of human head and neck cancer81. COX10 (Cytochrome C Oxidase Assembly Homolog 
10) is a member of a 14-gene classifier for colorectal cancer metastasis, identified by differential gene expression 
analysis of early and late stage primary colorectal cancer82.
Deregulation of the expression of genes involved in cholesterol homeostasis pathways has been associated with 
cancer development and progression83. In melanoma, the increased expression of 7 cholesterol synthesis pathway 
genes has been correlated with decreased patient survival84. Two genes (NR1H3, PLTP) with the ‘Positive regula-
tion of cholesterol efflux’ and/or ‘(positive regulation of) cholesterol homeostasis’ annotation were expressed at 
a decreased level in the M OMMs and three genes (APOE, MTTP, ABCA2) with one, or both, of the same anno-
tations, showed elevated expression in the M OMMs. NR1H3 (or Liver X Receptor Alpha isoform) is a Nuclear 
Receptor superfamily transcription factor which when activated by oxysterol binding drives cholesterol efflux85. 
Agonist activation of the Liver X Receptor Beta isoform (NR1H2) has been shown to suppress the growth and 
metastasis of melanoma cells by transcriptional induction of apolipoprotein-E86. Reduced NR1H3 expression is 
predictive of decreased recurrence-free survival in muscle-invasive bladder cancer87, and associated with reduced 
overall survival in hepatocellular carcinoma88. APOE (apolipoprotein-E) is a lipid transport protein essential for 
the normal catabolism of triglyceride-rich lipoproteins89. Elevated APOE expression is associated with lymph 
node metastasis of human gastric cancer90 and lung adenocarcinoma91, although it has been identified as a 
metastasis suppressor in vitro in human cutaneous melanoma92. PLTP (Phospholipid Transfer Protein) transfers 
phospholipids from triglyceride-rich lipoproteins to high density lipoprotein, and is involved in the uptake of 
cholesterol from peripheral cells and tissues. PLTP expression was increased in Grade IV human glioma relative 
to low grade glioma, and knockdown in vitro lead to the decreased migration of glioblastoma tumour cells93. In 
concept, the increased expression of PLTP in the NM OMMs observed in the present study may be consistent 
with the production by the tumours of interleukin 6, which has been shown to inhibit melanoma growth94. The 
increased expression of PLTP in the spontaneous regression phase of canine transmissible venereal tumour has 
previously been associated with increased IL-6 production95. The ATP-binding cassette transporter 2 (ABCA2) is 
a membrane-associated protein involved in sphingolipid transport. ABCA2 deficiency inhibits prostate tumour 
metastasis in vivo, potentially through reduction of the intracellular sphingolipid level96, whilst ABCA2 expres-
sion is increased in ovarian carcinoma metastases relative to primary tumours97.
In the present study, RT-qPCR analysis confirmed >two-fold differential expression between M and NM 
OMMs for 3 genes (CXCL12, APOBEC3A and RPL29). As fold change has been effectively employed to rank 
genes for their potential efficacy in gene expression level-based classification57,58, the 3 genes were selected 
for use in class prediction. Cross-validation was deployed in a preliminary evaluation to test the accuracy of 
a Linear Discriminant Analysis-based classifier featuring the 3 genes. The classification accuracies estimated 
were 94–100% (M OMMs) and 86–100% (NM OMMs), respectively. The LDA classifier performance will need 
to be validated by further retrospective, and prospective study. If the classification accuracy is confirmed, the 
cross-breed OMM metastasis-associated 3-gene expression signature would form the basis of an objective and 
quantitative predictive test for OMM metastasis that could make a significant contribution to the clinical man-
agement of canine OMM.
CXCL12 (C-X-C Motif Chemokine Ligand 12, or stromal cell-derived factor-1) is secreted by stromal cells and 
is a ligand for the G-protein coupled receptors CXCR4 and CXCR798. Binding of CXCL12 to CXCR4 activates four 
signal transduction pathways that induce cytoskeletal rearrangement, cell growth, angiogenesis, and anti-apoptotic 
effects98. Interaction between CXCL12 and CXCR4 has also been shown to mediate metastasis, and direct metastatic 
dissemination to organs expressing high levels of CXCL1299. Blocking CXCL12 binding to CXCR4 reduced the 
migration of human uveal melanoma cells in vitro100, and pulmonary metastasis of murine B16 cutaneous mela-
noma cells101. Low CXCL12 expression in human primary cutaneous melanomas has been associated with poor 
prognosis102 and shown to be predictive of metastasis103, and CXCL12 is one of 789 genes displaying reduced expres-
sion in ‘high grade’ human primary cutaneous melanomas that is a member of a 1,864 gene expression signature that 
delineates two classes of primary cutaneous melanomas with significantly different rates of metastasis104.
APOBEC3A (Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3A) encodes a cytidine deaminase 
which preferentially binds to the sequence 5′-(C/T)TCA in RNA or single-stranded DNA and converts cytosine to 
uracil. Deregulated APOBEC3A expression in cancer is believed to induce double strand breaks in genomic DNA 
activating DNA damage response pathways105. The repair of such breaks triggers the formation of single stranded 
DNAs which are substrates for APOBEC3A-mediated hypermutation, such that 5′-(C/T)TTA APOBEC3A mutation 
signatures occur in clusters (on one DNA strand) in multiple human cancers106. The extent of APOBEC-associated 
mutations correlates with APOBEC mRNA expression levels107. APOBEC3A-mediated mutagenesis occurs at dif-
ferent stages in different cancers108, and is thought to drive tumour evolution, including promoting metastasis109.
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RPL29 (Ribosomal protein L29) encodes a component of the 60 S ribosomal subunit. Beyond their role 
in ribosome assembly and protein translation, differential expression of ribosomal protein genes in cancer 
has been associated with ribosome-independent regulation of cell growth and proliferation, apoptosis, inva-
sion and metastasis110. Ribosome-free ribosomal proteins have been implicated as being both oncogenic and 
tumour-suppressors110. Silencing of RPL29 suppressed the proliferation of human pancreatic tumour cells and 
enhanced apoptosis111 suggesting an involvement in cell proliferation. However, RPL29 silencing had no effect 
on the viability of human metastatic melanoma cells112. The expression of a specific ribosomal protein has been 
shown to be a prognostic indicator for multiple human cancers113.
In human medicine, anti-angiogenics and matrix metalloproteinase inhibitors have been licenced for treat-
ment of tumour metastasis114. Cellular receptors in signal transduction pathways that control cell to cell and cell 
to ECM adhesion are targets for anti-metastatics in development115. Pro-metastatic gene expression in OMMs 
is a potential target for anti-metastasis therapeutics. Targeting the interaction between the CXCR4 receptor and 
CXCL12 has been evaluated as a strategy for inhibiting CXCR4-CXCL12 axis-mediated melanoma metastasis. 
Small molecule inhibitors of CXCR4 were shown to be effective at disrupting the liver metastasis of uveal mela-
noma cells in mice116, and migration of human cutaneous melanoma cells in vitro117. Chemical inhibition of the 
mutational activity of APOBEC3A (and APOBEC3B) is being evaluated as a cancer therapeutic118. Furthermore, 
demonstration of microRNA post-transcriptional regulation of APOBEC gene expression119 suggests the use of 
miR-mimics120 as a potential means of APOBEC deaminase inactivation119. Intriguingly, it has been postulated 
that APOBEC3A-mediated hypermutation could generate new tumour-specific antigens thereby enhancing the 
efficacy of immune stimulation therapies106. The potential for suppressing melanoma metastasis through acti-
vation of Liver X Receptors (LXR) using synthetic agonists has been investigated. Activation of the LXR Beta 
isoform (NR1H2) was shown to inhibit human and murine cutaneous melanoma cell migration in vitro and 
murine cutaneous melanoma cell metastasis in a mouse xenograft model86,121. If NR1H3 is the predominant 
LXR Receptor isoform expressed it remains to be seen if LXR agonists would initiate receptor activation with 
anti-metastatic effect. The up-regulation of FA pathway DNA repair genes in human cutaneous melanomas and 
canine OMM may be both pro-metastatic by negating the impact of increased genome instability, and contribute 
to melanoma metastases chemoresistance. Consequently, in concept, the use of FA pathway inhibitors122 may be 
an option for treatment of melanoma.
The major limitation of this study was that the number of NM OMMs included was restricted by the need to 
attempt to ensure that a primary tumour classified as ‘non-metastasising’ was only classified as such because it did 
not exhibit pro-metastatic gene expression as opposed to its metastasis potentially being prevented by a systemic 
adjuvant therapy. The consequence of the widespread use of the xenogenic melanoma vaccine in the UK was 
the exclusion of OMM biopsies from many dogs that had not developed metastatic disease. Furthermore, due 
to difficulties associated with collecting fresh canine tumour biopsies, FFPE biopsies of primary canine OMM 
(surgically removed at specialist veterinary oncology centres) were used in the study. However, data that is both 
biologically authentic and clinically-relevant has been obtained by Affymetrix microarray-based gene expression 
profiling of FFPE tissues123,124. Validation of the predictive accuracy of the 3-gene LDA classifier will be achieved 
through further retrospective, and prospective, studies featuring larger numbers of (optimally freshly collected) 
M and NM OMM biopsies. Ultimately, experimental investigations involving canine OMM cells will be necessary 
to confirm the functional consequences (e.g. in regard to cell migration) of metastasis-associated differential 
gene expression that are anticipated given gene function(s) and (in some cases) prior in vitro and in vivo study 
evidence.
Several of the differences in gene expression observed between primary canine OMMs that metastasised and 
OMMs that did not metastasise in this study have previously been associated with human cutaneous melanoma 
metastasis. The genes involved have been targets in proof of principle trials of potential anti-metastatic melanoma 
therapeutics. Other genes that exhibit differential expression between metastasising and non-metastasising pri-
mary canine OMMs may represent potential new targets for both canine and human cancer drugs. The results 
obtained in the present study suggest that OMMs in dogs may be responsive to anti-human melanoma metastasis 
therapeutics currently in clinical trials, or being evaluated through preclinical in vitro and in vivo model studies, 
and may be as likely as human melanomas to be responsive to therapeutics whose efficacy for treatment of human 
melanoma has yet to be investigated. Quantification of the expression of 3 genes, each of which displays a greater 
than two-fold differential expression between canine OMMs that do and do not metastasise, may be the potential 
basis for a test that would accurately predict canine OMM metastasis, and thereby assist a clinician to make an 
informed decision about the most appropriate treatment for a canine OMM patient.
Materials and Methods
ethics statements. This study was conducted with the approval of the ethics committees of the Animal 
Health Trust and the University of Liverpool, respectively. All methods were performed in accordance with the 
relevant guidelines and regulations. An OMM biopsy was only included in the study with the informed, written 
consent of the owner of the dog who bore the tumour. The treatment that a OMM patient received was unaffected 
by the inclusion of a biopsy of their tumour in the study.
tumour samples. FFPE biopsies of OMMs were collected (between 1993 and 2010) for histopathology 
from dogs attending the Clinical Oncology departments at the Animal Health Trust Centre for Small Animal 
Studies, University of Liverpool Small Animal Teaching Hospital, Dick White Referrals, and Colorado State 
University Veterinary Teaching Hospital. Biopsies were recovered by surgery performed (prior to any adju-
vant treatment) on dogs for whom complete staging and follow-up information were available. Metastasis was 
confirmed by abdominal ultrasound or computed tomography, and cytological/histological examination of ≥1 
regional lymph nodes. ‘Metastasising’ (M) OMM biopsies were from dogs that had pathological analysis and 
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diagnostic imaging-confirmed metastasis, and who died or were euthanased because of OMM metastasis <500 
days after surgery/biopsy (irrespective of adjuvant chemotherapy, including prednisolone, xenogeneic vaccine, 
and/or radiotherapy). ‘Non-metastasising’ (NM) OMM biopsies were from dogs without pathological analysis 
and imaging-confirmed metastasis, whom did not receive any adjuvant therapy, and who were still alive >540 
days post-surgery/biopsy.
RNA isolation and purification. The RecoverAll Total Nucleic Acid Isolation Kit, which facilitates 
on-column DNase digestion (ThermoFisher Scientific, Paisley, UK), was used to isolate total RNA from 
FFPE OMM biopsies. RNA samples were further purified by spin column filtration (OneStep PCR Inhibitor 
Removal Kit; Zymo Research, Freiburg, Germany) and additional DNase treatment (TURBO DNA-free kit; 
ThermoFisher Scientific, Paisley, UK). Finally, RNAs were concentrated (RNA Clean & Concentrator-5; Zymo 
Research, Freiburg, Germany) and quantified by RiboGreen fluorometry (Quant-iT RiboGreen RNA Assay Kit, 
ThermoFisher Scientific, Paisley, UK).
RNA sample selection. Reverse transcription-quantitative PCR (RT-qPCR) measurement of a 126 bp 
fragment of a 130–150 bp short interspersed nuclear element (SINE) that occurs every 5–8.3 kb in the canine 
genome125 was employed to assess the integrity of each FFPE RNA sample as described previously50. Procedural 
details are summarised in the Supplementary Information.
Genome-wide gene expression profiling. RNA amplification, labelling and microarray hybridisa-
tion. Fragmented, biotinylated single-stranded cDNA was prepared from 5.1 ng of each FFPE OMM RNA sam-
ple using the GeneChip WT Pico Reagent Kit (ThermoFisher Scientific, Paisley, UK). cDNA preparation involved 
target amplification by 11 cycles of adaptor-primer PCR and 14 h of in vitro transcription. Each cDNA was indi-
vidually hybridised to an array in a Canine Gene 1.1 ST Array Strip (ThermoFisher Scientific, Paisley, UK), in a 
proprietary hybridisation cocktail (ThermoFisher Scientific, Paisley, UK), for 20 h at 48 °C. Array strip washing 
and streptavidin-phycoerythrin staining were undertaken by the GeneAtlas System (ThermoFisher Scientific, 
Paisley, UK) Fluidics Station, and array scanning by the GeneAtlas System (ThermoFisher Scientific, Paisley, UK) 
Imaging Station.
Microarray data analysis. Microarray data was processed using the ‘Affymetrix Expression Console Software 
1.3’ (ThermoFisher Scientific, Paisley, UK). ‘Outlier arrays’ were first identified by review of exon-level probe set 
expression values created (using the RMA algorithm126) by quantile normalisation, log2 transformation and sig-
nal summarisation, respectively. Arrays with ≥1 sample quality, labelling quality or hybridisation quality metric 
value ≥2 standard deviations from the mean for all the arrays54 were excluded, and the raw probe-level signal 
intensity data for the remaining arrays re-processed to generate quantile normalised and log2-transformed exon 
and gene-level probe set expression values. Gene-level probe sets (‘Transcript clusters’) annotated as ‘crosshyb_
type’ = 1 (unique hybridisation target) and ‘category’ = ‘main’127, and for which the expression above background 
(detection above background p-value < 0.01128) of ≥l exon probe set could be detected in at least 30% of the 
OMMs in the M and/or NM group, were judged to be expressed in the OMMs and were included in further 
analyses.
Hierarchical clustering (average linkage; similarity metric = Pearson Correlation Coefficient) was performed 
using Cluster129, and Principal Component Analysis using the R stats package function prcomp130, in order to 
view the relationships between OMMs on the basis of their gene-level expression profiles. A two-tailed t-test 
for unpaired data was employed to identify genes exhibiting differential expression between M and NM OMMs 
that was statistically significant, adjusting P-values by permutation testing131 to correct for false positives arising 
from multiple testing. BLAST similarity search (against canine and human mRNAs and non-coding RNAs) was 
employed to attempt to establish the potential identity of Transcript clusters representing ‘predicted genes’, or for 
which gene annotation was unavailable.
Functional annotation analysis. The biological processes and pathways affected by the differences in gene 
expression observed between M and NM OMMs were identified using DAVID132,133. The functional annota-
tions associated with differentially expressed genes were compared with those ascribed to all Transcript clusters 
(‘crosshyb_type’ = 1 and ‘category’ = ‘main’) for which the expression of ≥1 exon probe set was detected above 
background in ≥30% of the tumours in the NM and/or M OMM cohort, and over-represented biological pro-
cesses and pathways identified.
Reverse transcription-quantitative PCR (RT-qPCR). RT-qPCR was employed for validation of differ-
ential gene expression. A unique region within the exon probe set that displayed the largest statistically significant 
fold-difference in expression between M and NM OMMs was the template for design (using Beacon Designer; 
Premier Biosoft, Palo Alto, USA) of a TaqMan or SYBR Green PCR assay. The expression level of each gene in 
each OMM sample was measured as the geometric Cq value calculated from triplicate PCR reactions performed 
using preamplified cDNAs, prepared from cDNAs previously screened for PCR inhibitors. A 71 bp fragment of 
a SINE125, present in the 3′-untranslated region of hundreds of canine mRNAs, was also assayed as a ‘reference 
gene’ for target gene expression measure normalisation134. Geometric mean Cq ≥35 were considered an unre-
liable measurement of gene expression and were excluded, as were the results of triplicate PCR assays with a Cq 
standard deviation of >0.5. Additional information is provided in the Supplementary Information.
RT-qPCR data analysis. Relative quantification of gene expression was performed using a modification of 
the delta-delta-Ct method which accounts for differences between the amplification efficiencies of target and 
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potentially multiple ‘reference’ genes135. Using qbase + (Biogazelle, Gent, Belgium), target gene geometric mean 
Cq values were converted to relative gene expression measurements (‘Normalised Relative Quantity; NRQ135) 
by application of a canine SINE125,134 geometric mean Cq-derived normalisation factor. A two-tailed t-test for 
unpaired data was performed on NRQ log10 transformations to identify genes exhibiting statistically significant 
differences in expression between M and NM OMMs.
Class prediction analysis. The R package SPreFuGED136 predicts the performance in class prediction 
of representatives of 10 classification functions and, through evaluation of the expression values obtained for 
the Transcript clusters expressed in the OMM, was employed to identify the optimal classification function for 
prediction of OMM ‘metastatic status’ (M or NM) on the basis of OMM gene expression. Linear Discriminant 
Analysis-based class prediction was undertaken using the R Package MASS130 lda function implemented in the R 
environment for statistical analyses137. The accuracy of class prediction, performed using RT-qPCR-derived gene 
expression measurements, was estimated by cross-validation. In random sampling cross-validation, on each of 
20 occasions the class (M or NM) of two M and one NM OMM, which constituted a ‘test data set’, were predicted 
after the classifier had been trained using the gene expression values (‘training data set’) obtained for the remain-
ing OMMs (90% of the tumours). In leave-one-out cross-validation, the class of each OMM was predicted after 
the classifier had been trained using the remaining (n-1) OMM gene expression data.
Data Availability
The microarray gene expression data generated during this study is available from the Gene Expression Omnibus 
repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129750).
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